Inceptionr LLC Takes Position in Kenvue Inc. $KVUE

Inceptionr LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, Holdings Channel reports. The fund acquired 14,751 shares of the company’s stock, valued at approximately $309,000.

Other institutional investors also recently bought and sold shares of the company. Truvestments Capital LLC acquired a new position in Kenvue during the 1st quarter valued at approximately $37,000. Trust Co. of Vermont lifted its stake in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the last quarter. Ransom Advisory Ltd acquired a new position in shares of Kenvue in the 1st quarter valued at $56,000. Finally, First Pacific Financial acquired a new position in shares of Kenvue in the 2nd quarter valued at $54,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 0.5%

Kenvue stock opened at $17.31 on Friday. The business’s 50-day moving average price is $16.06 and its 200 day moving average price is $19.56. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a market cap of $33.15 billion, a price-to-earnings ratio of 23.07 and a beta of 0.71. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s dividend payout ratio is 110.67%.

Analyst Ratings Changes

KVUE has been the subject of a number of research reports. Evercore ISI set a $18.00 price target on Kenvue in a research report on Tuesday, October 28th. JPMorgan Chase & Co. reduced their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a report on Friday, October 24th. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Finally, Bank of America decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.